[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stage-iia-prostate-cancer-ajcc-v8\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stage-iia-prostate-cancer-ajcc-v8":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100504723",false,"NCT05852041","rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance","A Pilot Study of rhPSMA-PET MRI Imaging for the Detection of Clinically Actionable Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance","Inclusion Criteria:\n\n* Healthy men (Eastern Cooperative Oncology Group \\[ECOG\\] 0-1), \\>= 18 years old with at least 10 year life expectancy\n* Histologically proven Gleason Grade Group 1 or 2 adenocarcinoma of the prostate\n* Last prostate cancer containing biopsy performed within 3-15 months (mo.) prior to screening. Biopsy must have been \\>= 10 core biopsy and informed by prior mpMRI\n* Prostate cancer categorized as low risk or favorable risk by National Comprehensive Cancer Network (NCCN) criteria (low risk is defined as T1c-T2a, prostate-specific antigen \\[PSA\\] \\\u003C 10ng\u002Fml, Gleason Grade Group 1 \\[Gleason 3+3=6\\] disease) and favorable intermediate risk as having no more than one of the following intermediate risk features, clinical T2b-T2c disease, PSA 10-20ng\u002Fml, Gleason Grade Group 2 \\[Gleason score 3+4=7\\])\n* Decipher genomic classifier score from prior biopsy \\>= 0.45\n* Institutional Review Board (IRB)-\u002FIndependent Ethics Committee (IEC)-approved written informed consent and privacy language as per national regulations must be obtained from the subject or legally authorized representative prior to any study-related procedures\n* Concurrent diseases and malignancies are permitted\n* Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on the study\n* Willing to undergo prostate biopsy prior to non-surgical treatment of prostate cancer and within 90 days of PET-MRI imaging\n\nExclusion Criteria:\n\n* Prior radiotherapy, surgery, chemotherapy, or hormonal therapy for prostate cancer\n* NCCN very low risk category (T1c and Gleason Grade Group 1 \\[Gleason score 3+3=6\\], PSA \\\u003C 10 ng\u002FmL, fewer than 3 prostate biopsy cores positive, =\\\u003C 50% cancer in any core, PSA density \\\u003C 0.15 ng\u002FmL\u002Fg)\n* Decipher score \\\u003C 0.45\n* Prior bladder outlet procedure (i.e,. holmium laser enucleation of the prostate \\[HoLEP\\], transurethral resection of the prostate \\[TURP\\], Urolift, Rezum)\n* Prohibited medications: use of 5 alpha reductase inhibitor or androgen deprivation therapy (i.e., leuprolide, relugolix) within 1 month of screening\n* Contra-indication or relative contra-indication to MRI (i.e., pacemaker)\n* History of hip replacement\n* Subject has received investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening",true,"MALE","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","This clinical trial evaluates whether positron emission tomography-magnetic resonance imaging (PET-MRI) using the radioactive drug radiohybrid prostate-specific membrane antigen (rhPSMA)-7.3 may help in detecting higher grade or stage disease in men with low and favorable intermediate risk prostate cancer who are candidates for active surveillance. A PET scan is a test that uses a radioactive drug and a computer to create images of how organs and tissues in the body are functioning. The radioactive drug used in this study, rhPSMA-7.3, attaches to the abnormal cells in the body at a different rate than normal cells which allows the scanner to create a detailed picture of how the body is working. An MRI scan uses strong magnets and computers to create detailed images of the soft tissue in your body. A multiparametric (mp)MRI is a type of MRI scan that creates a more detailed picture of the prostate gland. Using rhPSMA-73 with PET-MRI and mpMRI may be more effective in detecting higher grade or stage disease in men with low and favorable intermediate risk prostate cancer.",[26,27,28,29],"Prostate Adenocarcinoma","Stage I Prostate Cancer AJCC v8","Stage IIA Prostate Cancer AJCC v8","Stage IIB Prostate Cancer AJCC v8","RECRUITING","2026-06-30",{"date":33,"type":34},"2026-07-02","ACTUAL",{"date":36,"type":34},"2023-06-07",{"date":38,"type":20},"2035-06-07",{"name":40,"class":41},"Northwestern University","OTHER",""]